

Jaume Mora

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11496/publications.pdf>

Version: 2024-02-01

170
papers

17,895
citations

43973

48
h-index

14702

127
g-index

173
all docs

173
docs citations

173
times ranked

27827
citing authors

#	ARTICLE	IF	CITATIONS
1	Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events. <i>Cancer Reports</i> , 2023, 6, e1627.	0.6	9
2	SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas. <i>Journal of Controlled Release</i> , 2022, 342, 81-92.	4.8	12
3	Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patients. <i>Journal of Pathology</i> , 2022, , .	2.1	3
4	Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1. <i>Oncogene</i> , 2022, 41, 2638-2650.	2.6	10
5	How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de D��u in Barcelona, Spain. <i>ESMO Open</i> , 2022, 7, 100462.	2.0	5
6	AC-265347 Inhibits Neuroblastoma Tumor Growth by Induction of Differentiation without Causing Hypocalcemia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4323.	1.8	1
7	Autologous Stem-Cell Transplantation for High-Risk Neuroblastoma: Historical and Critical Review. <i>Cancers</i> , 2022, 14, 2572.	1.7	7
8	The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib. <i>EMBO Molecular Medicine</i> , 2022, 14, .	3.3	19
9	MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment. <i>BMC Cancer</i> , 2022, 22, .	1.1	5
10	WT1-Mutant Wilms Tumor Progression Is Associated With Diverting Clonal Mutations of CTNNB1. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e180-e183.	0.3	4
11	Functional Common and Rare <i>ERBB2</i> Germline Variants Cooperate in Familial and Sporadic Cancer Susceptibility. <i>Cancer Prevention Research</i> , 2021, 14, 441-454.	0.7	0
12	Recurrent Somatic Chromosomal Abnormalities in Relapsed Extraocular Retinoblastoma. <i>Cancers</i> , 2021, 13, 673.	1.7	9
13	Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma. <i>Cancers</i> , 2021, 13, 1264.	1.7	7
14	The transcriptional landscape of Shh medulloblastoma. <i>Nature Communications</i> , 2021, 12, 1749.	5.8	47
15	Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 338-349.	1.3	10
16	Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup. <i>Modern Pathology</i> , 2021, 34, 1558-1569.	2.9	28
17	GEIS 39: Phase II trial of nabpaclitaxel for the treatment of patient with multiply relapsed/refractory desmoplastic small round cell tumor (DSRCT) and Ewing sarcoma (EwS).. <i>Journal of Clinical Oncology</i> , 2021, 39, 11529-11529.	0.8	1
18	Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29121.	0.8	21

#	ARTICLE	IF	CITATIONS
19	Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma. <i>Oncogene</i> , 2021, 40, 5843-5853.	2.6	10
20	Subgroup and subtype-specific outcomes in adult medulloblastoma. <i>Acta Neuropathologica</i> , 2021, 142, 859-871.	3.9	34
21	A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression. <i>Nature Communications</i> , 2021, 12, 5578.	5.8	45
22	Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498.	5.8	237
23	Comprehensive Biology and Genetics Compendium of Wilms Tumor Cell Lines with Different WT1 Mutations. <i>Cancers</i> , 2021, 13, 60.	1.7	10
24	Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Martinez Sanz <i>et al</i> . , 2021, 9, e003751.		2
25	In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells. <i>Nature Communications</i> , 2020, 11, 5060.	5.8	60
26	LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma. <i>Cell Reports</i> , 2020, 30, 4567-4583.e5.	2.9	20
27	RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis. <i>Science Advances</i> , 2020, 6, .	4.7	24
28	The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies. <i>Frontiers in Pharmacology</i> , 2020, 11, 575009.	1.6	17
29	Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution. <i>Journal of Controlled Release</i> , 2020, 324, 440-449.	4.8	7
30	Nivolumab in paediatric cancer: children are not little adults. <i>Lancet Oncology</i> , The, 2020, 21, 474-476.	5.1	7
31	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. <i>Cell Reports Medicine</i> , 2020, 1, 100038.	3.3	24
32	Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program. <i>Acta Neuropathologica</i> , 2019, 138, 1053-1074.	3.9	106
33	Parathyroid hormone-like hormone plays a dual role in neuroblastoma depending on <i>PTH</i> 1R expression. <i>Molecular Oncology</i> , 2019, 13, 1959-1975.	2.1	8
34	Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	67
35	ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. <i>Communications Biology</i> , 2019, 2, 156.	2.0	73
36	Editorial: Proceedings From the 4th Memorial Alicia Pueyo Workshop: "Moving Towards a Cure for Diffuse Intrinsic Pontine Glioma". <i>Frontiers in Oncology</i> , 2019, 9, 42.	1.3	0

#	ARTICLE	IF	CITATIONS
37	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. <i>Nature Medicine</i> , 2019, 25, 1839-1842.	15.2	122
38	A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2019, 25, 1343-1357.	3.2	69
39	Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2019, 25, 2228-2240.	3.2	44
40	Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Preliminary results of HITS pilot/phase II study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10025-10025.	0.8	6
41	Glucosylated nanomicelles target glucose-avid pediatric patient-derived sarcomas. <i>Journal of Controlled Release</i> , 2018, 276, 59-71.	4.8	27
42	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. <i>Science</i> , 2018, 360, 331-335.	6.0	461
43	EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma. <i>International Journal of Cancer</i> , 2018, 143, 1188-1201.	2.3	35
44	A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 1355-1363.	3.2	24
45	EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. <i>Cancer Cell</i> , 2018, 33, 202-216.e6.	7.7	116
46	DNA methylation-based reclassification of olfactory neuroblastoma. <i>Acta Neuropathologica</i> , 2018, 136, 255-271.	3.9	59
47	Upfront Nephrectomy for the Treatment of Wilms Tumor: Outcomes and Predictors of Complications. <i>Journal of Child Science</i> , 2018, 08, e21-e26.	0.1	1
48	Chemotherapy and terminal skeletal muscle differentiation in WT mutant Wilms tumors. <i>Cancer Medicine</i> , 2018, 7, 1359-1368.	1.3	11
49	NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL. <i>Leukemia</i> , 2018, 32, 633-644.	3.3	35
50	Treatment of childhood astrocytomas with irinotecan and cisplatin. <i>Clinical and Translational Oncology</i> , 2018, 20, 500-507.	1.2	3
51	Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26732.	0.8	21
52	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. <i>Acta Neuropathologica</i> , 2018, 136, 239-253.	3.9	118
53	Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. <i>Nature Medicine</i> , 2018, 24, 1204-1215.	15.2	133
54	Protocolo de un dÃa vs protocolo de dos dÃas de adquisiciÃn mediante gammagrafÃa con leucocitos marcados in vitro para el diagnÃstico de infecciÃn osteoarticular. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2018, 37, 277-284.	0.0	3

#	ARTICLE	IF	CITATIONS
55	Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma. <i>Frontiers in Oncology</i> , 2018, 8, 127.	1.3	31
56	Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1902-1916.	1.9	48
57	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237.	3.9	86
58	Riskâ€‘benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. <i>Future Oncology</i> , 2018, 14, 2663-2676.	1.1	105
59	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. <i>Acta Neuropathologica</i> , 2018, 136, 327-337.	3.9	104
60	Tissue Compatibility of SNâ€‘38â€‘Loaded Anticancer Nanofiber Matrices. <i>Advanced Healthcare Materials</i> , 2018, 7, e1800255.	3.9	5
61	The combination of epigenetic drugs SAHA and HCI-2509 synergistically inhibits EWS-FLI1 and tumor growth in Ewing sarcoma. <i>Oncotarget</i> , 2018, 9, 31397-31410.	0.8	27
62	EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. <i>Nature Medicine</i> , 2017, 23, 483-492.	15.2	392
63	Tissue sampling in diffuse intrinsic pontine glioma (DIPG) at progression. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26492.	0.8	0
64	Second re-irradiation for DIPG progression, re-considering â€‘old strategiesâ€‘with new approaches. <i>Child's Nervous System</i> , 2017, 33, 849-852.	0.6	14
65	Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8. <i>Journal of Controlled Release</i> , 2017, 255, 108-119.	4.8	35
66	Genetic variants in the promoter region of the calciumâ€‘sensing receptor gene are associated with its downâ€‘regulation in neuroblastic tumors. <i>Molecular Carcinogenesis</i> , 2017, 56, 1281-1289.	1.3	11
67	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	7.7	836
68	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. <i>Cancer Cell</i> , 2017, 32, 520-537.e5.	7.7	716
69	Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). <i>Annals of Oncology</i> , 2017, 28, 2994-2999.	0.6	45
70	Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier. <i>Journal of Controlled Release</i> , 2017, 264, 34-44.	4.8	11
71	DNA Methylomes Reveal Biological Networks Involved in Human Eye Development, Functions and Associated Disorders. <i>Scientific Reports</i> , 2017, 7, 11762.	1.6	44
72	The whole-genome landscape of medulloblastoma subtypes. <i>Nature</i> , 2017, 547, 311-317.	13.7	787

#	ARTICLE	IF	CITATIONS
73	GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS). <i>British Journal of Cancer</i> , 2017, 117, 767-774.	2.9	17
74	DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1. <i>Cancer Letters</i> , 2017, 386, 196-207.	3.2	25
75	Neural crest derived progenitor cells contribute to tumor stroma and aggressiveness in stage 4/M neuroblastoma. <i>Oncotarget</i> , 2017, 8, 89775-89792.	0.8	4
76	The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. <i>Oncotarget</i> , 2016, 7, 8613-8624.	0.8	55
77	Establishment of a Conditionally Immortalized Wilms Tumor Cell Line with a Homozygous WT1 Deletion within a Heterozygous 11p13 Deletion and UPD Limited to 11p15. <i>PLoS ONE</i> , 2016, 11, e0155561.	1.1	10
78	Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination. <i>Cancer Letters</i> , 2016, 380, 10-19.	3.2	22
79	Safety of bevacizumab in patients younger than 4 years of age. <i>Clinical and Translational Oncology</i> , 2016, 18, 464-468.	1.2	11
80	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	0.8	160
81	Use of 3D Prototypes for Complex Surgical Oncologic Cases. <i>World Journal of Surgery</i> , 2016, 40, 889-894.	0.8	49
82	SN-38-loaded nanofiber matrices for local control of pediatric solid tumors after subtotal resection surgery. <i>Biomaterials</i> , 2016, 79, 69-78.	5.7	40
83	Hipoestesia mentoniana como manifestaci3n de met4stasis mandibular diagnosticada en la gammagraf4a 132sea. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2016, 35, 34-37.	0.0	0
84	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. <i>Cancer Cell</i> , 2016, 29, 379-393.	7.7	438
85	Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 647-653.	1.3	39
86	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	5.1	274
87	Landscape of early clinical trials for childhood and adolescence cancer in Spain. <i>Clinical and Translational Oncology</i> , 2016, 18, 708-713.	1.2	4
88	RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF- κ B pathway, independently of the fusion oncoprotein. <i>Oncotarget</i> , 2016, 7, 46283-46300.	0.8	12
89	Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens. <i>Oncotarget</i> , 2016, 7, 16112-16129.	0.8	19
90	Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression. <i>Oncotarget</i> , 2016, 7, 21840-21852.	0.8	85

#	ARTICLE	IF	CITATIONS
91	The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin. <i>Oncotarget</i> , 2015, 6, 18875-18890.	0.8	74
92	Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7). <i>Clinical and Translational Oncology</i> , 2015, 17, 521-529.	1.2	14
93	Results of the survey about the use of the SPECT-CT in bone pathology in Spain during 2012. <i>Medicine Nucleaire</i> , 2015, 39, 444-449.	0.2	0
94	DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights. <i>Epigenomics</i> , 2015, 7, 1137-1153.	1.0	40
95	Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived Xenografts. <i>Pharmaceutical Research</i> , 2015, 32, 2889-2900.	1.7	11
96	Desmoplastic small round cell tumor 20 years after its discovery. <i>Future Oncology</i> , 2015, 11, 1071-1081.	1.1	39
97	Orphan drugs revisited: cost-effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 331-340.	0.7	7
98	Low-grade gliomas in children: single institutional experience in 198 cases. <i>Child's Nervous System</i> , 2015, 31, 1447-1459.	0.6	10
99	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E5564-73.	3.3	355
100	Simultaneous <i>KIT</i> mutation and succinate dehydrogenase (<i>SDH</i>) deficiency in a patient with a gastrointestinal stromal tumour and Carney-Stratakis syndrome: a case report. <i>Histopathology</i> , 2014, 65, 712-717.	1.6	7
101	The Genomic Landscape of Pediatric Ewing Sarcoma. <i>Cancer Discovery</i> , 2014, 4, 1326-1341.	7.7	415
102	Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors. <i>Cancer Discovery</i> , 2014, 4, 216-231.	7.7	596
103	Recurrent activating <i>ACVR1</i> mutations in diffuse intrinsic pontine glioma. <i>Nature Genetics</i> , 2014, 46, 457-461.	9.4	423
104	Cytogenetic Prognostication Within Medulloblastoma Subgroups. <i>Journal of Clinical Oncology</i> , 2014, 32, 886-896.	0.8	263
105	Intra-arterial chemotherapy for retinoblastoma. Challenges of a prospective study. <i>Acta Ophthalmologica</i> , 2014, 92, 209-215.	0.6	27
106	Long noncoding RNA <i>EWSAT1</i> -mediated gene repression facilitates Ewing sarcoma oncogenesis. <i>Journal of Clinical Investigation</i> , 2014, 124, 5275-5290.	3.9	81
107	Caveolin-1 is down-regulated in alveolar rhabdomyosarcomas and negatively regulates tumor growth. <i>Oncotarget</i> , 2014, 5, 9744-9755.	0.8	19
108	Brain stem tumors in children and adolescents: single institutional experience. <i>Child's Nervous System</i> , 2013, 29, 1321-1331.	0.6	28

#	ARTICLE	IF	CITATIONS
109	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2013, 14, 1200-1207.	5.1	307
110	The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis. <i>Carcinogenesis</i> , 2013, 34, 268-276.	1.3	35
111	Mutational heterogeneity in cancer and the search for new cancer-associated genes. <i>Nature</i> , 2013, 499, 214-218.	13.7	4,761
112	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 126, 917-929.	3.9	146
113	Genetics of pheochromocytoma and paraganglioma in Spanish pediatric patients. <i>Endocrine-Related Cancer</i> , 2013, 20, L1-L6.	1.6	44
114	Burkitt's lymphoma treatment in a rural hospital in Sierra Leone. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2013, 107, 653-659.	0.7	5
115	Polymorphisms in the Calcium-Sensing Receptor Gene Are Associated with Clinical Outcome of Neuroblastoma. <i>PLoS ONE</i> , 2013, 8, e59762.	1.1	13
116	EphA2-Induced Angiogenesis in Ewing Sarcoma Cells Works through bFGF Production and Is Dependent on Caveolin-1. <i>PLoS ONE</i> , 2013, 8, e71449.	1.1	34
117	What is a pediatric tumor?. <i>Clinical Oncology in Adolescents and Young Adults</i> , 2012, , 7.	0.8	6
118	A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma. <i>Clinical Cancer Research</i> , 2012, 18, 2012-2023.	3.2	59
119	DNA Hypomethylation Affects Cancer-Related Biological Functions and Genes Relevant in Neuroblastoma Pathogenesis. <i>PLoS ONE</i> , 2012, 7, e48401.	1.1	31
120	Activated growth signaling pathway expression in Ewing sarcoma and clinical outcome. <i>Pediatric Blood and Cancer</i> , 2012, 58, 532-538.	0.8	26
121	A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. <i>Journal of Clinical Investigation</i> , 2012, 122, 2983-2988.	3.9	347
122	Identification of tumoral glial precursor cells in neuroblastoma. <i>Cancer Letters</i> , 2011, 312, 73-81.	3.2	9
123	Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents. <i>Pediatric Blood and Cancer</i> , 2011, 57, 69-75.	0.8	12
124	Antiangiogenic treatment as a preoperative management of alveolar soft part sarcoma. <i>Pediatric Blood and Cancer</i> , 2011, 57, 1071-1073.	0.8	20
125	Axenfeld-Rieger ocular anomaly and retinoblastoma caused by constitutional chromosome 13q deletion. <i>Pediatric Blood and Cancer</i> , 2010, 54, 480-482.	0.8	6
126	Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm. <i>Human Molecular Genetics</i> , 2010, 19, 1651-1668.	1.4	66

#	ARTICLE	IF	CITATIONS
127	Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. <i>Molecular Cancer</i> , 2010, 9, 277.	7.9	57
128	Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature. <i>Clinical Cancer Research</i> , 2010, 16, 1532-1541.	3.2	86
129	Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma. <i>BMC Cancer</i> , 2009, 9, 44.	1.1	26
130	The calcium-sensing receptor and parathyroid hormone-related protein are expressed in differentiated, favorable neuroblastic tumors. <i>Cancer</i> , 2009, 115, 2792-2803.	2.0	23
131	Treatment of disseminated paraganglioma with gemcitabine and docetaxel. <i>Pediatric Blood and Cancer</i> , 2009, 53, 663-665.	0.8	10
132	Comprehensive characterization of neuroblastoma cell line subtypes reveals bilineage potential similar to neural crest stem cells. <i>BMC Developmental Biology</i> , 2009, 9, 12.	2.1	54
133	Use of angioembolization as an effective technique for the management of pediatric solid tumors. <i>Journal of Pediatric Surgery</i> , 2009, 44, 1848-1855.	0.8	16
134	Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and Docetaxel. <i>Journal of Pediatric Hematology/Oncology</i> , 2009, 31, 723-729.	0.3	73
135	Differential expression of genes mapping to recurrently abnormal chromosomal regions characterize neuroblastic tumours with distinct ploidy status. <i>BMC Medical Genomics</i> , 2008, 1, 36.	0.7	9
136	Fibrolamellar Hepatocellular Carcinoma in an Infant and Literature Review. <i>Journal of Pediatric Hematology/Oncology</i> , 2008, 30, 968-971.	0.3	9
137	Successful treatment of childhood intramedullary spinal cord astrocytomas with irinotecan and cisplatin. <i>Neuro-Oncology</i> , 2007, 9, 39-46.	0.6	24
138	Primary Ewing sarcoma of the tentorium presenting with intracranial hemorrhage in a child. <i>Journal of Neurosurgery: Pediatrics</i> , 2007, 107, 411-415.	0.8	27
139	Different CTNNB1 mutations as molecular genetic proof for the independent origin of four Wilms tumours in a patient with a novel germ line WT1 mutation. <i>Journal of Medical Genetics</i> , 2007, 44, 393-396.	1.5	25
140	Comprehensive analysis of tumoral DNA content reveals clonal ploidy heterogeneity as a marker with prognostic significance in locoregional neuroblastoma. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 385-396.	1.5	10
141	Molecular pathways linking the pheochromocytoma susceptibility genes' response. <i>Pediatric Blood and Cancer</i> , 2007, 49, 1052-1053.	0.8	0
142	High TGF β 2-Smad Activity Confers Poor Prognosis in Glioma Patients and Promotes Cell Proliferation Depending on the Methylation of the PDGF-B Gene. <i>Cancer Cell</i> , 2007, 11, 147-160.	7.7	446
143	Epstein-Barr virus related opsoclonus-myoclonus-ataxia does not rule out the presence of occult neuroblastic tumors. <i>Pediatric Blood and Cancer</i> , 2006, 47, 964-967.	0.8	17
144	Pediatric paraganglioma: An early manifestation of an adult disease secondary to germline mutations. <i>Pediatric Blood and Cancer</i> , 2006, 47, 785-789.	0.8	20

#	ARTICLE	IF	CITATIONS
145	Epithelioid sarcoma with SYT-SSX1 fusion gene expression: molecular and cytogenetic analysis. <i>Cancer Genetics and Cytogenetics</i> , 2005, 162, 50-56.	1.0	11
146	Primitive hematopoietic malignant neoplasm presenting as a CD43-positive, small round, blue-cell tumor in an infant. <i>Pediatric Blood and Cancer</i> , 2005, 45, 865-866.	0.8	3
147	EMP3, a Myelin-Related Gene Located in the Critical 19q13.3 Region, Is Epigenetically Silenced and Exhibits Features of a Candidate Tumor Suppressor in Glioma and Neuroblastoma. <i>Cancer Research</i> , 2005, 65, 2565-2571.	0.4	154
148	Comprehensive analysis of the 9p21 region in neuroblastoma suggests a role for genes mapping to 9p21 in the biology of favourable stage 4 tumours. <i>British Journal of Cancer</i> , 2004, 91, 1112-1118.	2.9	12
149	Positional gene expression analysis identifies 12q overexpression and amplification in a subset of neuroblastomas. <i>Cancer Genetics and Cytogenetics</i> , 2004, 154, 131-137.	1.0	30
150	Origin of neuroblastic tumors: clues for future therapeutics. <i>Expert Review of Molecular Diagnostics</i> , 2004, 4, 293-302.	1.5	25
151	Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol. <i>Cancer</i> , 2003, 98, 1283-1291.	2.0	67
152	Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma. <i>Cancer Letters</i> , 2003, 197, 119-124.	3.2	25
153	Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. <i>Cancer Research</i> , 2003, 63, 4538-46.	0.4	65
154	Evolving significance of prognostic markers associated with treatment improvement in patients with Stage 4 neuroblastoma. <i>Cancer</i> , 2002, 94, 2756-2765.	2.0	28
155	Novel regions of allelic imbalance identified by genome-wide analysis of neuroblastoma. <i>Cancer Research</i> , 2002, 62, 1761-7.	0.4	17
156	Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease. <i>Cancer</i> , 2001, 91, 435-442.	2.0	23
157	N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. <i>Medical and Pediatric Oncology</i> , 2001, 36, 227-230.	1.0	114
158	Genetic heterogeneity and clonal evolution in neuroblastoma. <i>British Journal of Cancer</i> , 2001, 85, 182-189.	2.9	32
159	Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. <i>Nature</i> , 2001, 409, 207-211.	13.7	901
160	Molecular Genetics of Neuroblastoma and the Implications for Clinical Management: A Review of the MSKCC Experience. <i>Oncologist</i> , 2001, 6, 263-268.	1.9	15
161	N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. <i>Medical and Pediatric Oncology</i> , 2001, 36, 227-230.	1.0	1
162	Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease. <i>Cancer</i> , 2001, 91, 435-42.	2.0	4

#	ARTICLE	IF	CITATIONS
163	Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. <i>Clinical Cancer Research</i> , 2001, 7, 1358-61.	3.2	42
164	Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. <i>Cancer Research</i> , 2001, 61, 6892-8.	0.4	79
165	Large cell non-Hodgkin lymphoma of childhood. , 2000, 88, 186-197.		49
166	Spontaneous remission of congenital acute nonlymphoblastic leukemia with normal karyotype in twins. <i>Medical and Pediatric Oncology</i> , 2000, 35, 110-113.	1.0	23
167	Laser-capture microdissected Schwannian and neuroblastic cells in stage 4 neuroblastomas have the same genetic alterations. <i>Medical and Pediatric Oncology</i> , 2000, 35, 534-537.	1.0	11
168	Clinical Categories of Neuroblastoma Are Associated with Different Patterns of Loss of Heterozygosity on Chromosome Arm 1p. <i>Journal of Molecular Diagnostics</i> , 2000, 2, 37-46.	1.2	46
169	Primary epidural non-Hodgkin lymphoma: Spinal cord compression syndrome as the initial form of presentation in childhood non-Hodgkin lymphoma. , 1999, 32, 102-105.		35
170	Listeriosis in pediatric oncology patients. , 1998, 83, 817-820.		13